依洛尤单抗的不良反应

Adverse Reactions of PCSK9 Inhibitor Evolocumab

前蛋白转化酶枯草溶菌素9(PCSK9)抑制药是近年来备受关注的新型降脂药物。PCSK9抑制药可显著降低低密度脂蛋白胆固醇(LDL-C)水平,并在改善心血管事件方面有着积极影响。尽管PCSK9抑制药具有较高的安全性及耐受性,但了解其不良反应对于临床治疗仍具有重要的指导意义。该文通过查阅相关文献综述依洛尤单抗(evolocumab)的不良反应,包括注射部位反应、鼻咽炎、肌痛、神经认知障碍等。

The inhibitor of proprotein convertase subtilisin/kexin type 9(PCSK9)is a new kind of lipid-lowering drug that have attracted much attention in recent years.PCSK9 inhibitors significantly reduce low density lipoprotein-cholesterol(LDL-C)levels and have a positive impact in preventing cardiovascular events.Although PCSK9 inhibitors have high safety and tolerability,understanding their adverse reactions still has important significance for clinical treatment.This article reviews the adverse reaction reports of evolocumab,including injection site reaction,nasopharyngitis,myalgia and neurocognitive impairment.